Home - Products - Cell Cycle/DNA Damage - CDK - CDK12-IN-3

CDK12-IN-3

CAS No. 2220184-50-7

CDK12-IN-3( —— )

Catalog No. M33320 CAS No. 2220184-50-7

CDK12-IN-3 is a selective and potent CDK12 inhibitor with anti-tumor activity, which can be used to study malignant tumors.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	345	In Stock
5MG	312	In Stock
10MG	511	In Stock
25MG	1074	In Stock
50MG	1758	In Stock
100MG	2325	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

CDK12-IN-3
Note

Research use only, not for human use.
Brief Description

CDK12-IN-3 is a selective and potent CDK12 inhibitor with anti-tumor activity, which can be used to study malignant tumors.
Description

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Cell Cycle/DNA Damage
Target

CDK
Recptor

CDK
Research Area

——
Indication

——

Chemical Information

CAS Number

2220184-50-7
Formula Weight

470.52
Molecular Formula

C23H28F2N8O
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 250 mg/mL (531.33 mM; Ultrasonic )
SMILES

CC(C)n1cnc2c(NCc3nc4ccc(F)c(F)c4[nH]3)nc(nc12)N1CCCC[C@H]1CCO
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Johannes JW, et al. Structure-Based Design of Selective Noncovalent CDK12 Inhibitors. ChemMedChem. 2018 Feb 6;13(3):231-235.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

AZ5576

AZ5576, a potent and highly selective CDK9 inhibitor, can be used for research on Hematological Malignancy .
Avotaciclib

Avotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.
Roniciclib

A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.

Sign In Join Free